IL99754A - Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis - Google Patents

Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis

Info

Publication number: IL99754A
Authority: IL; Israel
Prior art keywords: mbp; rats; fed; suppression; disease
Prior art date: 1990-10-15

Application number

IL9975491A

Other languages

English (en)

Hebrew (he)

Other versions

IL99754A0 (en

Original Assignee

Autoimmune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-15

Filing date

1991-10-15

Publication date

1996-08-04

1991-10-15 Application filed by Autoimmune Inc filed Critical Autoimmune Inc

1992-08-18 Publication of IL99754A0 publication Critical patent/IL99754A0/xx

1996-08-04 Publication of IL99754A publication Critical patent/IL99754A/en

Links

238000011282 treatment Methods 0.000 title claims description 25
201000006417 multiple sclerosis Diseases 0.000 title claims description 17
206010039073 rheumatoid arthritis Diseases 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
206010071155 Autoimmune arthritis Diseases 0.000 title claims description 6
239000012634 fragment Substances 0.000 title abstract description 47
230000001225 therapeutic effect Effects 0.000 claims abstract description 6
206010003246 arthritis Diseases 0.000 claims description 36
108010041390 Collagen Type II Proteins 0.000 claims description 24
102000000503 Collagen Type II Human genes 0.000 claims description 24
102000008186 Collagen Human genes 0.000 claims description 18
108010035532 Collagen Proteins 0.000 claims description 18
229920001436 collagen Polymers 0.000 claims description 18
102000006386 Myelin Proteins Human genes 0.000 claims description 14
108010083674 Myelin Proteins Proteins 0.000 claims description 14
210000005012 myelin Anatomy 0.000 claims description 11
241000283690 Bos taurus Species 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 8
102000001187 Collagen Type III Human genes 0.000 claims description 6
108010069502 Collagen Type III Proteins 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims 2
241001465754 Metazoa Species 0.000 abstract description 82
208000023275 Autoimmune disease Diseases 0.000 abstract description 42
210000001744 T-lymphocyte Anatomy 0.000 abstract description 34
238000000034 method Methods 0.000 abstract description 28
230000001404 mediated effect Effects 0.000 abstract description 10
230000000069 prophylactic effect Effects 0.000 abstract description 3
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 184
102000047918 Myelin Basic Human genes 0.000 description 172
101710107068 Myelin basic protein Proteins 0.000 description 172
241000700159 Rattus Species 0.000 description 118
230000001629 suppression Effects 0.000 description 86
201000002491 encephalomyelitis Diseases 0.000 description 73
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 67
201000010099 disease Diseases 0.000 description 66
210000004027 cell Anatomy 0.000 description 64
208000009386 Experimental Arthritis Diseases 0.000 description 57
230000035611 feeding Effects 0.000 description 55
241000187479 Mycobacterium tuberculosis Species 0.000 description 43
210000004989 spleen cell Anatomy 0.000 description 39
102000036639 antigens Human genes 0.000 description 38
108091007433 antigens Proteins 0.000 description 38
239000000427 antigen Substances 0.000 description 35
230000003053 immunization Effects 0.000 description 35
238000002649 immunization Methods 0.000 description 35
230000000694 effects Effects 0.000 description 31
108091003079 Bovine Serum Albumin Proteins 0.000 description 30
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
239000002953 phosphate buffered saline Substances 0.000 description 26
229940098773 bovine serum albumin Drugs 0.000 description 25
238000011694 lewis rat Methods 0.000 description 25
210000001165 lymph node Anatomy 0.000 description 25
230000006698 induction Effects 0.000 description 24
230000004044 response Effects 0.000 description 24
239000002671 adjuvant Substances 0.000 description 19
238000002474 experimental method Methods 0.000 description 18
238000012546 transfer Methods 0.000 description 18
230000035755 proliferation Effects 0.000 description 17
241000700199 Cavia porcellus Species 0.000 description 16
108010058846 Ovalbumin Proteins 0.000 description 15
229940092253 ovalbumin Drugs 0.000 description 15
101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 14
230000001712 encephalitogenic effect Effects 0.000 description 14
230000009696 proliferative response Effects 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 13
238000011161 development Methods 0.000 description 12
238000000338 in vitro Methods 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
230000028993 immune response Effects 0.000 description 11
210000004988 splenocyte Anatomy 0.000 description 11
201000008827 tuberculosis Diseases 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
210000000952 spleen Anatomy 0.000 description 9
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
230000003393 splenic effect Effects 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
210000003414 extremity Anatomy 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
241000283707 Capra Species 0.000 description 5
108010062580 Concanavalin A Proteins 0.000 description 5
102000002812 Heat-Shock Proteins Human genes 0.000 description 5
108010004889 Heat-Shock Proteins Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 5
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
230000002917 arthritic effect Effects 0.000 description 5
230000006472 autoimmune response Effects 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000006285 cell suspension Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
230000016784 immunoglobulin production Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 5
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010023232 Joint swelling Diseases 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000036039 immunity Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
206010070834 Sensitisation Diseases 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
230000002962 histologic effect Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000004957 immunoregulator effect Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
102000013415 peroxidase activity proteins Human genes 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
230000002688 persistence Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000008313 sensitization Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
101001018362 Bos taurus Myelin basic protein Proteins 0.000 description 2
241000700198 Cavia Species 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000007815 allergy Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
201000004982 autoimmune uveitis Diseases 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
102000054064 human MBP Human genes 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
238000004091 panning Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
238000003825 pressing Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
-1 semisolid Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
241000894007 species Species 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101000685083 Centruroides infamatus Beta-toxin Cii1 Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
206010013142 Disinhibition Diseases 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
206010014025 Ear swelling Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010017577 Gait disturbance Diseases 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100137555 Mus musculus Prg2 gene Proteins 0.000 description 1
208000011644 Neurologic Gait disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033885 Paraparesis Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010037714 Quadriplegia Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
108090000787 Subtilisin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
238000009171 T-cell vaccination Methods 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
241000159243 Toxicodendron radicans Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000002299 affinity electrophoresis Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000000599 auto-anti-genic effect Effects 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000009826 distribution Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002888 effect on disease Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
102000034240 fibrous proteins Human genes 0.000 description 1
108091005899 fibrous proteins Proteins 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
239000000834 fixative Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
208000010726 hind limb paralysis Diseases 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000007365 immunoregulation Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000007981 phosphate-citrate buffer Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
210000002975 pon Anatomy 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
230000001005 suppressogenic effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000024664 tolerance induction Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000011637 wistar furth rat Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Rheumatology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Liquid Crystal (AREA)
Liquid Crystal Display Device Control (AREA)
Control Of Indicators Other Than Cathode Ray Tubes (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IL9975491A 1990-10-15 1991-10-15 Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis IL99754A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US59693690A	1990-10-15	1990-10-15

Publications (2)

Publication Number	Publication Date
IL99754A0 IL99754A0 (en)	1992-08-18
IL99754A true IL99754A (en)	1996-08-04

Family

ID=24389347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9975491A IL99754A (en)	1990-10-15	1991-10-15	Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis

Country Status (13)

Country	Link
US (1)	US6019971A (fr)
EP (1)	EP0553291B1 (fr)
JP (1)	JP2635444B2 (fr)
KR (1)	KR0140841B1 (fr)
AT (1)	ATE319474T1 (fr)
AU (2)	AU9023791A (fr)
CA (1)	CA2092905C (fr)
DE (1)	DE69133516T2 (fr)
ES (1)	ES2258261T3 (fr)
HU (1)	HUT69942A (fr)
IL (1)	IL99754A (fr)
NO (1)	NO314878B1 (fr)
WO (1)	WO1992006708A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6645504B1 (en)	1987-06-24	2003-11-11	Autoimmune Inc.	Bystander suppression of type I diabetes by oral administration of glucagon
US5843445A (en) *	1987-06-24	1998-12-01	Autoimmune, Inc.	Method of treating rheumatoid arthritis with type II collagen
US5869054A (en) *	1987-06-24	1999-02-09	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of autoantigens
US5849298A (en) *	1987-06-24	1998-12-15	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of bovine myelin
CA2092905C (fr) *	1990-10-15	2002-01-08	Howard L. Weiner	Traitement de maladies auto-immunes par l'administration orale d'autoantigenes
AU664561B2 (en) *	1991-06-21	1995-11-23	University Of Cincinnati, The	Orally administrable therapeutic proteins and method of making
US6613332B1 (en)	1991-06-21	2003-09-02	The University Of Cincinnati	Oral administration of therapeutic proteins
DE4125400C2 (de) *	1991-07-31	2000-08-17	Edwin Klaus	Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen
BR9306042A (pt) *	1992-02-28	1997-11-18	Autoimmune Inc	Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
EP0662838A4 (fr) *	1992-09-25	1996-07-24	Autoimmune Inc	Procede de traitement de la polyarthrite rhumatoide avec du collagene de type ii.
DK0603992T4 (da) *	1992-12-22	2001-03-05	Univ Cincinnati	Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
DK0609471T3 (da) *	1993-02-02	2000-05-29	Edwin Dr Klaus	Anvendelse af kollagen til behandling af sygelige ledprocesser
AU674584B2 (en) *	1993-06-02	1997-01-02	Tvw Telethon Institute For Child Health Research	Cryptic peptides for use in inducing immunologic tolerance
GB9319429D0 (en)	1993-09-21	1993-11-03	London Health Ass	Methods and products for controlling immune responses in mammals
US6251396B1 (en)	1994-11-18	2001-06-26	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en)	1994-11-18	2002-04-30	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5856446A (en) *	1995-07-07	1999-01-05	Autoimmune Inc.	Method of treating rheumatoid arthritis with low dose type II collagen
CA2238439C (fr) *	1996-01-05	2004-11-30	Autoimmune, Inc.	Procede de preparation de collagene de type ii
WO1997046253A2 (fr) *	1996-06-03	1997-12-11	Powderject Vaccines, Inc.	Immunotherapie pour maladie auto-immune
WO1998006861A2 (fr) *	1996-08-15	1998-02-19	Agrivax Incorporated	Administration d'antigenes tolerogeniques via des plantes comestibles ou des produits derives de plantes
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20050208114A1 (en) *	1998-03-24	2005-09-22	Petito George D	Composition and method for healing tissues
US7691829B2 (en) *	1998-03-24	2010-04-06	Petito George D	Composition and method for healing tissues
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US7371385B2 (en) *	2000-05-12	2008-05-13	Oregon Health & Science University	Method of treating immune pathologies with low dose estrogen
US7462486B2 (en) *	2000-05-12	2008-12-09	Oregon Health & Science University	Methods of selecting T cell receptor V peptides for therapeutic use
WO2001089557A2 (fr)	2000-05-24	2001-11-29	The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services	Methodes de prevention des accidents vasculaires cerebraux moyennant l'induction d'une tolerance a e-selectin
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
CA2575604A1 (fr) *	2004-07-30	2006-02-02	Oregon Health And Science University	Procedes de detection et de traitement de troubles auto-immuns
EP1838348B1 (fr)	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
ES2396555T3 (es)	2004-12-15	2013-02-22	Janssen Alzheimer Immunotherapy	Anticuerpos que reconocen péptido beta amiloide
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
ES2498040T3 (es)	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
CN104922199A (zh) *	2015-07-14	2015-09-23	无限极（中国）有限公司	一种保护骨关节组合物及其应用
EP3621985B1 (fr)	2017-05-11	2026-06-24	Avicenna Nutraceutical, LLC	Procédés de production de collagène
AU2020349481A1 (en)	2019-09-16	2022-04-14	Fibrobiologics, Inc.	Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4350682A (en) *	1979-05-11	1982-09-21	Lescarden Ltd.	Cartilage extraction processes and products
JP2633881B2 (ja) *	1986-06-30	1997-07-23	マサチューセッツインスティテュートオブテクノロジー	免疫調節組成物及びそれらの使用
CA1302880C (fr) *	1986-07-25	1992-06-09	Peter Koepff	Agents pour le traitement de l'arthrose
JP2512796B2 (ja) *	1987-06-24	1996-07-03	オートイミュン・インコーポレイテッド	自己抗原の経口投与による自己免疫疾患の治療法
US5849298A (en) *	1987-06-24	1998-12-15	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of bovine myelin
US5843445A (en) *	1987-06-24	1998-12-01	Autoimmune, Inc.	Method of treating rheumatoid arthritis with type II collagen
US5399347A (en) *	1987-06-24	1995-03-21	Autoimmune, Inc.	Method of treating rheumatoid arthritis with type II collagen
CA1340012C (fr) *	1987-08-17	1998-08-25	Trustees Of Leland Stanford Jr. University	Determinant peptidique associe a l'immunite
DK0506785T3 (da) *	1989-12-20	2000-07-24	Autoimmune Inc	Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener
US5075112A (en) *	1990-02-12	1991-12-24	Cartilage Technologies Inc.	Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
HUT61896A (en) *	1990-03-02	1993-03-29	Autoimmune Inc	Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
CA2092905C (fr) *	1990-10-15	2002-01-08	Howard L. Weiner	Traitement de maladies auto-immunes par l'administration orale d'autoantigenes
DE4125400C2 (de) *	1991-07-31	2000-08-17	Edwin Klaus	Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen

1991
- 1991-10-15 CA CA002092905A patent/CA2092905C/fr not_active Expired - Lifetime
- 1991-10-15 JP JP4500704A patent/JP2635444B2/ja not_active Expired - Lifetime
- 1991-10-15 AT AT92900084T patent/ATE319474T1/de not_active IP Right Cessation
- 1991-10-15 DE DE69133516T patent/DE69133516T2/de not_active Expired - Lifetime
- 1991-10-15 WO PCT/US1991/007542 patent/WO1992006708A1/fr not_active Ceased
- 1991-10-15 HU HU9301089A patent/HUT69942A/hu unknown
- 1991-10-15 AU AU90237/91A patent/AU9023791A/en not_active Abandoned
- 1991-10-15 EP EP92900084A patent/EP0553291B1/fr not_active Expired - Lifetime
- 1991-10-15 ES ES92900084T patent/ES2258261T3/es not_active Expired - Lifetime
- 1991-10-15 IL IL9975491A patent/IL99754A/en not_active IP Right Cessation
- 1991-10-15 KR KR1019930701083A patent/KR0140841B1/ko not_active Expired - Fee Related
1993
- 1993-04-14 NO NO19931372A patent/NO314878B1/no not_active IP Right Cessation
1995
- 1995-06-05 US US08/463,946 patent/US6019971A/en not_active Expired - Lifetime
- 1995-09-01 AU AU30409/95A patent/AU693232B2/en not_active Ceased

Also Published As

Publication number	Publication date
KR0140841B1 (ko)	1998-06-01
AU9023791A (en)	1992-05-20
JPH05508662A (ja)	1993-12-02
ATE319474T1 (de)	2006-03-15
DE69133516D1 (de)	2006-05-04
CA2092905A1 (fr)	1992-04-16
NO314878B1 (no)	2003-06-10
HUT69942A (en)	1995-09-28
DE69133516T2 (de)	2006-08-10
WO1992006708A1 (fr)	1992-04-30
EP0553291B1 (fr)	2006-03-08
HU9301089D0 (en)	1993-07-28
ES2258261T3 (es)	2006-08-16
IL99754A0 (en)	1992-08-18
JP2635444B2 (ja)	1997-07-30
EP0553291A4 (en)	1994-11-30
AU693232B2 (en)	1998-06-25
AU3040995A (en)	1995-11-30
EP0553291A1 (fr)	1993-08-04
NO931372L (no)	1993-05-18
KR930702026A (ko)	1993-09-08
CA2092905C (fr)	2002-01-08
NO931372D0 (no)	1993-04-14
US6019971A (en)	2000-02-01

Legal Events

Date	Code	Title
1997-01-10	FF	Patent granted
1997-06-10	KB	Patent renewed
1998-02-22	KB	Patent renewed
2002-02-10	KB	Patent renewed
2006-01-15	KB	Patent renewed
2010-05-17	KB	Patent renewed
2012-06-28	EXP	Patent expired

Publication	Publication Date	Title
US5849298A (en)	1998-12-15	Treatment of multiple sclerosis by oral administration of bovine myelin
US6019971A (en)	2000-02-01	Treatment of autoimmune arthritis by oral administration of collagen
US5869054A (en)	1999-02-09	Treatment of multiple sclerosis by oral administration of autoantigens
EP0359783B2 (fr)	2002-04-17	Traitement de maladies auto-immunitaires par administration orale d'auto-antigenes
US20050208061A1 (en)	2005-09-22	Treatment of autoimmune diseases by oral administration of autoantigens
AU651097B2 (en)	1994-07-14	Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
Zhang et al.	1990	Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen.
Higgins et al.	1988	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments.
JP2004026797A (ja)	2004-01-29	ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
US5961977A (en)	1999-10-05	Method of treating or preventing autoimmune uveoretinitis in mammals
JPH09511990A (ja)	1997-12-02	経口寛容および／またはＴｈ２増強サイトカインを用いた自己免疫疾患の治療
KR100263164B1 (ko)	2000-08-01	Ii형 콜라겐의 펩티드를 유효성분으로 함유하는 콜라겐 관절염 치료제